The American College of Radiology lauded the AMA’s policy update that recognizes the importance of screening mammography starting at age 40.
The American College of Radiology lauded the American Medical Association’s policy update this week that recognizes the importance of breast cancer screening mammography starting at age 40.
Paul Ellenbogen, MD, FACR, chair of the ACR Board of Chancellors, noted that since mammography screening became widespread, the breast cancer death rate in the U.S. had dropped more than 30 percent - even among women ages 40 to 49.
“The ACR urges women ages 40-and-over to receive annual mammograms,” he said in a statement. “Women need access to these lifesaving exams. Government and insurers should not get in the way of this care.”
The ACR noted its support of several items in the AMA’s position, including that the AMA:
• recognizes the mortality reduction benefit of screening mammography and supports its use as a tool to detect breast cancer.
• believes that beginning at the age of 40 years, all women should be eligible for screening mammography.
The AMA also supports insurance coverage for screening mammography, and encourages physicians to discuss the benefits and risks with their patients.
The ACR also praised the AMA’s resolution expressing concern about the recent recommendations by the United States Preventative Service Task Force that would limit screening to women over 50. The AMA also encouraged the USPSTF to “implement procedures that allow for meaningful input on recommendation development from specialists and stakeholders in the topic area under study.”
“The bottom line is that discontinuing regular mammograms may save a few dollars in the short term, but will result in thousands more breast cancer deaths each year,” Barbara Monsees, MD, chair of the ACR Breast Imaging Commission, said in a statement. “That human cost is too high.”
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
New AI-Enabled Portable Ultrasound May Facilitate 50 Percent Reduction in Cardiac Imaging Scan Time
March 28th 2025Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which will be unveiled at the American College of Cardiology (ACC) conference.